Andrew David Levin - Aug 9, 2021 Form 4 Insider Report for Eliem Therapeutics, Inc. (ELYM)

Role
Director
Signature
/s/ Alan Hambelton, Attorney-in-Fact
Stock symbol
ELYM
Transactions as of
Aug 9, 2021
Transactions value $
$0
Form type
4
Date filed
8/11/2021, 05:14 PM
Next filing
Jun 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELYM Stock Option (Right to Buy) Award $0 +20K $0.00 20K Aug 9, 2021 Common Stock 20K $12.50 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/36th of the shares will vest on each monthly anniversary of August 1, 2021.
F2 Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.